Literature DB >> 25795133

Augmentation of autologous T cell reactivity with acute myeloid leukemia (AML) blasts by Toll-like receptor (TLR) agonists.

RuiKun Zhong1, Hongying Li, Karen Messer, Thomas A Lane, Jiehua Zhou, Edward D Ball.   

Abstract

This study investigated whether TNF-α, Toll-like receptors (TLRs) 7/8 agonist resiquimod (R848), the TLR4 agonist lipopolysaccharide (LPS) and their combinations can enhance autologous AML-reactive T cell generation in an in vitro culture. AML peripheral blood or bone marrow mononuclear cells were cultured in medium supplemented with GM-CSF/IL-4 to induce dendritic cell (DC) differentiation of AML blasts (AML-DC). The impact of TNF-α, LPS, R848 and their combinations on AML-DC cultures was analyzed. Significantly enhanced CD80, CD40, CD83, CD54, HLA-DR and CD86 expression of AML cells was observed by addition of TNF-α, LPS, R848 alone or combinations. Induced CD80 expression of AML cells was significantly higher through the combination of TNF-α, LPS and R848 (T + L + R) than that by T alone. CTL induced from T + L + R, T + R, T + L, L + R and R, but not T, L alone stimulated cultures showed significantly higher IFN-γ release than the medium control in response to autologous AML cells. IFN-γ release by T + L + R was significantly higher than T or L alone, and T + R was significantly higher than T alone. CTL generated from T + L + R, T + L, T + R, L + R and L alone exerted significantly higher AML cell killing than medium control. AML cell killing by T + L + R and T + R was significantly higher than T or R alone. These results indicate that the combination of T + L + R induces a significantly enhanced antigen presentation effect of AML-DC. We speculate that the complementary effects of reagent combinations may better address the heterogeneity of responses to any single agent in AML cells from different patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25795133      PMCID: PMC4742236          DOI: 10.1007/s00262-015-1680-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  38 in total

Review 1.  Hematopoiesis sculpted by pathogens: Toll-like receptors and inflammatory mediators directly activate stem cells.

Authors:  Julie R Boiko; Lisa Borghesi
Journal:  Cytokine       Date:  2011-11-12       Impact factor: 3.861

Review 2.  Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact.

Authors:  Dorian McIlroy; Marc Gregoire
Journal:  Cancer Immunol Immunother       Date:  2003-06-24       Impact factor: 6.968

3.  Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia.

Authors:  A Woiciechowsky; S Regn; H J Kolb; M Roskrow
Journal:  Leukemia       Date:  2001-02       Impact factor: 11.528

4.  A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

Authors:  H Jonuleit; A Giesecke-Tuettenberg; T Tüting; B Thurner-Schuler; T B Stuge; L Paragnik; A Kandemir; P P Lee; G Schuler; J Knop; A H Enk
Journal:  Int J Cancer       Date:  2001-07-15       Impact factor: 7.396

5.  Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.

Authors:  Veit Hornung; Simon Rothenfusser; Stefanie Britsch; Anne Krug; Bernd Jahrsdörfer; Thomas Giese; Stefan Endres; Gunther Hartmann
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

6.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

7.  Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8.

Authors:  Florian Heil; Hiroaki Hemmi; Hubertus Hochrein; Franziska Ampenberger; Carsten Kirschning; Shizuo Akira; Grayson Lipford; Hermann Wagner; Stefan Bauer
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

8.  TLR9 signals after translocating from the ER to CpG DNA in the lysosome.

Authors:  Eicke Latz; Annett Schoenemeyer; Alberto Visintin; Katherine A Fitzgerald; Brian G Monks; Cathrine F Knetter; Egil Lien; Nadra J Nilsen; Terje Espevik; Douglas T Golenbock
Journal:  Nat Immunol       Date:  2004-01-11       Impact factor: 25.606

9.  Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets.

Authors:  Tomoki Ito; Ryuichi Amakawa; Tsuneyasu Kaisho; Hiroaki Hemmi; Kenichirou Tajima; Kazutaka Uehira; Yoshio Ozaki; Hideyuki Tomizawa; Shizuo Akira; Shirou Fukuhara
Journal:  J Exp Med       Date:  2002-06-03       Impact factor: 14.307

10.  Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.

Authors:  Christian Schürch; Carsten Riether; Michael A Amrein; Adrian F Ochsenbein
Journal:  J Exp Med       Date:  2013-02-11       Impact factor: 14.307

View more
  6 in total

Review 1.  Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

Authors:  Lisa Pleyer; Peter Valent; Richard Greil
Journal:  Int J Mol Sci       Date:  2016-06-27       Impact factor: 5.923

2.  Imiquimod inhibits growth and induces differentiation of myeloid leukemia cell lines.

Authors:  Eva Villamón; Javier González-Fernández; Esperanza Such; José Vicente Cervera; Daniel Gozalbo; M Luisa Gil
Journal:  Cancer Cell Int       Date:  2018-01-30       Impact factor: 5.722

Review 3.  Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells.

Authors:  Shayda Hemmati; Tamanna Haque; Kira Gritsman
Journal:  Front Oncol       Date:  2017-11-13       Impact factor: 6.244

Review 4.  Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications.

Authors:  Nicola Stefano Fracchiolla; Bruno Fattizzo; Agostino Cortelezzi
Journal:  Stem Cells Int       Date:  2017-08-21       Impact factor: 5.443

5.  The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells.

Authors:  Xueheng Guo; Ning Wu; Yingli Shang; Xin Liu; Tao Wu; Yifan Zhou; Xin Liu; Jiaoyan Huang; Xuebin Liao; Li Wu
Journal:  Front Immunol       Date:  2017-02-21       Impact factor: 7.561

Review 6.  Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes.

Authors:  Luana Chiquetto Paracatu; Laura G Schuettpelz
Journal:  Front Immunol       Date:  2020-06-17       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.